Navigation Links
GlaxoSmithKline's Drug Will Become New Clinical Gold Standard by 2012 for the Treatment of Relapsed/Refractory CLL
Date:1/20/2009

An Agent Showing Improvement in Overall Response Rate Would Earn Higher Patient Share in U.S. Than Europe, According to a New Report from Decision Resources

WALTHAM, Mass., Jan. 20 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that GlaxoSmithKline's ofatumumab will become Decision Resources' proprietary clinical gold-standard treatment for relapsed/refractory chronic lymphocytic leukemia (CLL) by 2012. This shift is due to ofatumumab's competitive advantages over the current gold standard--Bayer Schering Pharma's Campath/MabCampath--in efficacy (overall response rate), safety and tolerability (hematological toxicities and infections) and delivery (frequency).

The new report entitled Relapsed/Refractory Chronic Lymphocytic Leukemia: Physicians Are Eager for Increasingly Efficacious Therapies in the Refractory Setting finds that an agent showing improvement in overall response rate, compared to Campath/MabCampath, for high-risk, relapsed/refractory patients would earn a higher patient share in the U.S. (50 percent) than in Europe (40 percent). This is because European oncologists are more cost-conscious than U.S. physicians and such a drug would bear a slight price increase.

"The European market is more sensitive to increases in price than the U.S. market, and the price of Campath/MabCampath is already very high in both markets. Even though European oncologists forecast a more conservative patient share for such an agent, a patient share of 40 percent is considerable in the relapsed/refractory CLL market," stated Andrew Merron, Ph.D., analyst at Decision Resources.

About the Report

Relapsed/Refractory Chronic Lymphocytic Leukemia: Physicians Are Eager for Increasingly Efficacious Therapies in the Refractory Setting is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    Natalia Morales                              Elizabeth Marshall
    Decision Resources                           Decision Resources, Inc.
    781-296-2691                                 781-296-2563
    nmorales@dresources.com                      emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Micro-Preemie Survives to Become March of Dimes 2009 National Ambassador
2. Zumas Rescue Ranch becomes a Federal 501C3
3. MinuteClinic Becomes Participating Provider With Blue Cross and Blue Shield of Florida
4. Medscape Physician Connect Becomes Largest Online Physician Social Network with More than 100,000 Physicians
5. Dental Network of America Becomes Largest National Dental Network in the U.S.
6. Mega Pediatric Group Allows Doctors to Focus on Patient Care as the Business Side of Private Practice Becomes More Difficult to Sustain
7. When the Caregiver Becomes the Patient
8. K-State helps nursing home staff become comfortable with residents sexual expression
9. 26 percent of sleepless children become overweight
10. Two Colorado Surgeons Become Pioneers In Microsurgical DIEP Flap Breast Reconstruction
11. Coors of Las Vegas Becomes New Distributor of RecoveryX
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
(Date:6/24/2016)... Los Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... plastic surgery procedures that most people are unfamiliar with. The article goes on to ... known procedures, but also many of these less common operations such as calf and ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association ... it will receive two significant new grants to support its work to advance ... 25th anniversary by recognizing patients, medical professionals and scientists for their work in ...
(Date:6/24/2016)... ... ... BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a ... an hour by 2020 and then adjusting it yearly to increase at the same rate ... assure the wage floor does not erode again, and make future increases more predictable. , ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® ... Group (TGIG), has initiated cultivation and processing operations at its production facility, and ... Nevada. , Puradigm is the manufacturer of a complete system of proactive air ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... innovative inhaled drugs, announced today that it was added ... reconstituted its comprehensive set of U.S. and global ... is an important milestone for Pulmatrix," said Chief Executive ... awareness of our progress in developing drugs for crucial ...
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... 2022" report to their offering. ... with kidney failure, it replaces the function of kidneys by ... and thus the treatment helps to keep the patient body,s ... Increasing number of ESRD patients & substantial healthcare ...
Breaking Medicine Technology: